Abstract

AtriCure, Inc. will report its second-quarter 2026 results on July 23, 2026 Post-Mkt; this preview compiles last quarter’s results, street forecasts for the current quarter, business segment dynamics, and prevailing analyst opinions to frame likely outcomes and key stock drivers.

Market Forecast

Street expectations for the current quarter point to revenue of 152.05 million US dollars, up 16.81% year over year, with adjusted EPS estimated at 0.01 US dollars (+107.28% YoY) and EBIT around 1.50 million US dollars (+120.56% YoY). There is no formal gross-margin or net-margin forecast disclosed for the quarter; consensus signals a return to modest profitability with costs broadly contained.

The company’s core revenue engine remains surgical ablation and left atrial appendage management, with product utilization and account penetration seen as the primary levers shaping quarterly momentum. Within the portfolio, atrial clip devices stand out as a key growth contributor after delivering 48.38 million US dollars last quarter, supported by consistent procedure volumes and stable pricing; pain management (cryo nerve block) showed continued traction with 22.36 million US dollars and is positioned as a follow-through growth vector this quarter.

Last Quarter Review

In the first quarter of 2026, AtriCure, Inc. generated 141.25 million US dollars in revenue (+14.26% YoY) with a gross profit margin of 77.39%, GAAP net profit attributable to shareholders of 0.11 million US dollars (net profit margin 0.08%), and adjusted EPS of 0.00 (up 100% YoY per reported metrics).

A notable financial highlight was positive EBIT of 0.53 million US dollars versus a consensus expectation for a loss, reflecting disciplined operating control and favorable mix. By business line, atrial clip devices contributed 48.38 million US dollars, open-heart ablation 39.08 million US dollars, international 25.04 million US dollars, pain management 22.36 million US dollars, and minimally invasive ablation 6.39 million US dollars, underscoring a diversified revenue base anchored by procedural therapies.

Current Quarter Outlook

Main business: surgical therapies remain the revenue backbone

The company’s surgical therapy portfolio continues to anchor top-line performance, with procedure-driven demand patterns that depend on hospital scheduling, capacity, and training pipelines. In the last reported quarter, unit volumes and account activity were sufficient to deliver 141.25 million US dollars in revenue and a 77.39% gross margin, setting a high base exiting the first quarter. Coming into the second quarter, analysts expect a step-up to 152.05 million US dollars, implying a healthy throughput of surgical cases and sustained adoption within established accounts as well as incremental account additions.

A recurrent feature of the model is the balance between price, mix, and utilization. Clip systems and surgical ablation technologies tend to support premium mix, and the prior quarter’s gross margin suggests favorable absorption and cost discipline. For the current quarter, there is no formal gross-margin figure in street models, but the revenue acceleration implied by consensus typically assumes that manufacturing and freight inputs remain stable and that product mix skews toward higher-value devices in line with historical trends. Any deviation—whether from procedure timing, supply chain costs, or mix—can quickly influence margin conversion, so investors will parse segment commentary for signals about sustainability into the second half.

Operating leverage is the other critical dimension. With EBIT forecast at about 1.50 million US dollars for the quarter, models embed a cautious but improving expense trajectory. Given that first-quarter EBIT came in slightly positive relative to expectations for a loss, the second-quarter step-up is viewed as an early indicator that operating efficiency and revenue scale can translate to incremental profitability. The degree of operating expense growth relative to revenue will likely frame management’s full-year profitability cadence.

Most promising business: left atrial appendage management and pain management

Left atrial appendage management—anchored by atrial clip systems—was the single largest contributor last quarter at 48.38 million US dollars and remains central to near-term growth dynamics. The underlying drivers are procedural volume trends, procedural success rates that reinforce surgeon confidence, and steady account expansion. With consensus looking for a double-digit revenue increase this quarter, a repeat of last quarter’s strong product contribution would position the business to outpace corporate averages, particularly if case volumes rise into the summer procedure window.

Pain management (cryo nerve block) registered 22.36 million US dollars last quarter and continues to present a follow-through growth opportunity. Adoption patterns in thoracic and certain general surgical settings can lift utilization, and the attach-rate for cryo-based solutions alongside established procedures provides an incremental revenue stream without necessarily requiring new account creation. The business’s contribution in the current quarter will hinge on case throughput and utilization consistency; if these hold, the segment can add to growth while enhancing mix. The key is that even modest utilization growth against a stable fixed-cost base can have outsized contribution margins, improving overall earnings quality.

International revenues, at 25.04 million US dollars last quarter, offer an additional pathway to upside if underlying distributor and direct markets sustain momentum. While currency swings and regional procedure calendars introduce normal variability, steady international uptake supports the breadth of the revenue base. For the second quarter, stabilizing inputs and consistent procedural access would support international growth comparable to or better than the corporate average, adding a secondary layer of resilience to total revenue.

Key stock-price drivers this quarter: revenue trajectory, margin durability, and forward guidance

The first and most visible yardstick will be the revenue print versus the 152.05 million US dollars consensus. The prior quarter demonstrated that the company can deliver volume and mix sufficient for mid-teens growth; achieving or beating the 16.81% YoY implied for the second quarter would help validate the trajectory into the second half. Conversely, a shortfall would likely raise questions about case timing, utilization patterns, or one-off dynamics such as hospital schedule shifts.

Gross-margin durability will also be closely watched, given the 77.39% result last quarter. Without a formal margin forecast, commentary on product mix, pricing, and cost inputs will serve as proxies for the margin trend. If mix remains favorable and there are no new cost headwinds, investors will expect margin to remain in the vicinity of recent results. Any meaningful drift lower could dampen the translation of revenue growth into profit, while confirmation of stability would support the projected step-up in EBIT.

Finally, forward-looking commentary and any updated full-year outlook will likely influence the stock’s reaction. The market is modeling an early stage of profitability improvement, with adjusted EPS moving from 0.00 last quarter to a modest 0.01 this quarter on higher revenue and controlled spending. Management’s discussion of pipeline productivity, account expansion, and selling efficiency—combined with expense phasing through the second half—will shape expectations for the pace of EPS expansion. Clear confirmation that operating leverage is building could amplify the stock’s response to an in-line revenue result, while a conservative expense stance could cap upside even with a revenue beat.

Analyst Opinions

The prevailing view among covering analysts is bullish, with multiple Buy ratings reiterating confidence in the revenue trajectory and an improving earnings profile. BTIG has been consistently constructive: analyst Marie Thibault reiterated a Buy rating and has carried targets such as 54.00 US dollars and 45.00 US dollars in recent reports, emphasizing sustained outperformance, manageable competitive dynamics, and underappreciated growth. Stifel Nicolaus maintained a Buy rating with a 50.00 US dollars target, signaling confidence in the company’s ability to execute on procedure-led growth and margin normalization. Piper Sandler has also reaffirmed a Buy stance in its latest communication.

The core of these positive views centers on three themes that map directly to the quarter’s setup. First, the revenue composition is seen as resilient, driven by broad-based procedural demand across surgical therapies and supported by international contributions. This aligns with consensus for 152.05 million US dollars in second-quarter revenue and a 16.81% YoY increase; analysts believe the cadence is consistent with last quarter’s 141.25 million US dollars and 14.26% YoY expansion. Second, the margin outlook is viewed as gradually improving: a 77.39% gross margin last quarter demonstrates product mix and cost control conducive to earnings formation as revenue scales. The EBIT swing to a 0.53 million US dollars profit in the first quarter versus expected losses bolsters the case that operating leverage is beginning to take hold.

Third, several analysts frame valuation relative to a multi-quarter ramp in profitability, noting that even small increments in adjusted EPS—consensus sees 0.01 US dollars this quarter, implying +107.28% YoY—can credibly translate as the fixed-cost base is absorbed. The implied 1.50 million US dollars EBIT forecast (+120.56% YoY) is modest in absolute terms but directionally important. In their view, as long as product adoption trends persist and segment contributions remain diversified—anchored by atrial clip devices at 48.38 million US dollars last quarter and an ongoing build in pain management—visibility improves for incremental operating gains through the second half.

Within the bullish cohort, institutional notes commonly emphasize the predictive power of utilization and account expansion data points. Positive indications around case volumes, stable supply chains, or steady pricing can each support revenue realization at or above the implied 16.81% growth. Analysts are also attentive to expense discipline; reiteration that investment in commercial and R&D is calibrated to revenue growth would underwrite the EBIT inflection anticipated this quarter. Alternatively, if spending growth outpaces revenue, the path to EPS expansion could extend, even with healthy top-line performance. For now, the consensus assumes a measured approach.

In summary, analysts leaning bullish expect a second-quarter report that confirms revenue momentum and shows early stages of sustained earnings formation. They will scrutinize the composition of growth—particularly the contributions of atrial clip systems and pain management—alongside commentary on margin drivers and operating spend. A delivery near or above 152.05 million US dollars in revenue with stable gross margin would validate the upward bias in estimates, while constructive full-year commentary would likely reinforce Buy ratings that are currently dominant across the institutional landscape.